title: Immune response against gene therapy vectors: influence of synovial fluid on adeno-associated virus mediated gene transfer to chondrocytes.
abstract: Intraarticular gene transfer with adeno-associated virus (AAV) vectors may allow efficient therapeutic transgene expression within the joint. In an effort to understand potential obstacles (particularly immunity against AAV vectors) to intraarticular gene therapy better, our objective was to determine whether synovial fluid (SF) influenced AAV-mediated gene transfer to chondrocytes. SF and sera from 21 patients with joint diseases were collected. Neutralizing activity against AAV/interleukin-4 (IL-4) was determined by assessing the ability of SF or serum to inhibit AAV/IL-4 transduction to the C20A4 chondrocytes. IgGs were purified from SF by salt-dependent chromatography. Anti-AAV IgG levels were determined by ELISA in the SF. SF and sera from all the patients inhibited AAV-mediated gene transfer to chondrocytes. Six SF out of 21 exerted a stronger inhibition. Serum from healthy patients were also inhibitory. Purified IgGs from SF exhibited inhibition patterns similar to those seen with whole SF. Anti-AAV IgG were found in SF from 13 patients out of 18. Moreover, in the SF, anti-AAV IgG level was correlated with the neutralizing activity (p < 0.001, r = 0.716). A correlation was observed between levels of inhibition by the SF and serum (P < 0.0001, r = 0.813). Inhibition of AAV/IL-4 infection of C20A4 cells by SF and sera was abolished by increasing the number of AAV/IL-4 particles. SF from patients with joint disease consistently inhibited AAV infection of chondrocytes in vitro. This effect was ascribable to IgG, most probably directed against AAV. In the future, these data may be useful for tailoring intraarticular AAV-mediated gene therapy to individual patients.
authors.affiliation: UPRES EA-3408, Léonard de Vinci Medical School and Department of Rheumatology, Avicenne Teaching Hospital, Bobigny, AP-HP, University of Paris 13, France.
authors.forename: Virginie
authors.initials: V
authors.lastname: Cottard
authors.forename: Chiara
authors.initials: C
authors.lastname: Valvason
authors.forename: Géraldine
authors.initials: G
authors.lastname: Falgarone
authors.forename: Didier
authors.initials: D
authors.lastname: Lutomski
authors.forename: Marie-Christophe
authors.initials: MC
authors.lastname: Boissier
authors.forename: Natacha
authors.initials: N
authors.lastname: Bessis
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000032:analysis / Q000302:isolation & purification; D002460:Cell Line; D019902:Chondrocytes / Q000276:immunology* / Q000821:virology; D000229:Dependovirus / Q000235:genetics / Q000276:immunology*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000302:isolation & purification; D007592:Joint Diseases / Q000276:immunology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D013582:Synovial Fluid / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G